No.10, Yanfa 2nd Road
Hsinchu Science Park
Hsinchu City 30076
Taiwan
886 3 666 9596
https://www.easywellbio.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo:
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. James Lee Ph.D. | President | N/D | N/D | N/D |
Dr. Yu-Hsing Tu Ph.D. | Chief Science Officer | N/D | N/D | N/D |
Dr. She Bin-Ru Ph.D. | Chief Technical Officer of Regenerative Medicine Division | N/D | N/D | N/D |
Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine. In addition, it provides medical devices. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
La calificación ISS Governance QuickScore de Easywell Biomedicals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.